Comparative effectiveness of certolizumab pegol, abatacept and biosimilar infliximab in patients with rheumatoid arthritis treated in routine care. Observational data from the Danish DANBIO registry emulating a randomized trial

ConclusionThe surrogate randomization procedure enabled head ‐to‐head comparison of certolizumab pegol, abatacept and CT‐P13. Although some differences in the estimated effectiveness were observed across drugs, confidence intervals were wide and statistical significance was not reached.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatology - July 2, 2019 Category: Rheumatology Authors: Kathrine L. Gr øn, Bente Glintborg, Mette Nørgaard, Frank Mehnert, Mikkel Østergaard, Lene Dreyer, Niels S. Krogh, Jakob B. Bjorner, Merete L. Hetland Tags: Full Length Source Type: research